Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Standard Biotools (LAB) over the last 15 years, with Q3 2025 value amounting to $1.6 million.

  • Standard Biotools' Amortizatization of Intangibles fell 1074.47% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 3884.43%. This contributed to the annual value of $7.4 million for FY2024, which is 3361.61% down from last year.
  • As of Q3 2025, Standard Biotools' Amortizatization of Intangibles stood at $1.6 million, which was down 1074.47% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Amortizatization of Intangibles ranged from a high of $3.0 million in Q1 2021 and a low of $1.1 million during Q4 2024
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $2.8 million (2023), whereas its average is $2.4 million.
  • Per our database at Business Quant, Standard Biotools' Amortizatization of Intangibles soared by 50.54% in 2021 and then crashed by 5957.14% in 2024.
  • Standard Biotools' Amortizatization of Intangibles (Quarter) stood at $3.0 million in 2021, then decreased by 0.2% to $3.0 million in 2022, then dropped by 5.66% to $2.8 million in 2023, then plummeted by 59.57% to $1.1 million in 2024, then skyrocketed by 38.69% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.